11 results about "Ulinastatin" patented technology

The present application relates to the technical field of new materials, in particular to a porous ulinastatin adsorbent with a responsive shell and a preparation method thereof.The porous ulinastatin adsorbent with a responsive shell is a full-synthetic polymer matrix, and has a solid structure.A high-crosslinking-degree polyvinyl alcohol / styrene / divinylbenzene core and a MOF nanoparticle-enhanced framework endow the porous ulinastatin adsorbent with a responsive shell with excellent mechanical strength, and the porous ulinastatin adsorbent with a responsive shell can withstand the pressure in an industrial chromatography column and is not prone to breakage.Because both recognition and desorption are physical processes, the replacement frequency and overall cost of the porous ulinastatin adsorbent with a responsive shell in the production process are greatly reduced, and a reliable guarantee is provided for industrial large-scale and continuous production.

The invention relates to the technical field of new materials, in particular to a porous ulinastatin adsorbent with a response shell layer and a preparation method of the porous ulinastatin adsorbent. The porous ulinastatin adsorbent with the response shell layer is a fully-synthetic polymer matrix and is firm in structure. The porous ulinastatin adsorbent with the response shell layer is endowed with excellent mechanical strength by a high-crosslinking-degree polyvinyl alcohol / styrene / divinyl benzene core and an MOF nanoparticle reinforced skeleton, can bear pressure in an industrial chromatographic column, and is not easy to break. Due to the fact that identification and desorption are physical processes, the replacement frequency and the overall cost of the porous ulinastatin adsorbent with the response shell layer in the production process are greatly reduced, and a reliable guarantee is provided for industrial large-scale continuous production.

The invention discloses a method for industrially and efficiently generating ulinastatin, which comprises the following steps of: mixing female urine waste liquid from which HCG (Human Chorionic Gonadotropin) is extracted with sodium bentonite to obtain a mixture; carrying out first-stage solid-liquid separation on the mixture, and collecting a liquid part to obtain filtrate; adsorbing the filtrate by using an adsorption column of ion exchange resin, and then eluting the adsorbed resin by using a sodium chloride solution to obtain an eluent; the pH of the eluent is adjusted to be alkaline, diatomite is used as a filter aid, second-stage solid-liquid separation is conducted on the eluent with the pH adjusted, and sediment is collected and is ulinastatin. According to the method, three technical modules of sodium bentonite pretreatment, anion exchange adsorption and high-pH precipitation-diatomite refined filtration are creatively combined, and the HCG production waste liquid is ingeniously used as the raw material, so that many defects in the prior art are successfully overcome, and powerful support is provided for industrial production of ulinastatin.

The invention relates to the technical field of biology, in particular to a method for extracting ulinastatin in urine. According to the prepared composite adsorbent, porous ferroferric oxide magnetic microspheres serve as cores, the surfaces of the porous ferroferric oxide magnetic microspheres are coated with silicon dioxide, amination and formylation modification are carried out, then the porous ferroferric oxide magnetic microspheres react with triethylene tetramine and 3-fluoro-4-formylphenylboronic acid in sequence, finally, ulinastatin serves as a template molecule, and 4-(2-aminoethyl)-1, 2, 4-triazolo [3, 4-b]-1, 2, 4-triazolo [3, 4-b]-1, 2, 4-triazolo [3, 4-b]-1, 2, 4-b]-1, the ulinastatin composite adsorbent is prepared from ulinastatin and 1, 2-benzenediol hydrochloride as functional monomers, the prepared composite adsorbent accurately recognizes and captures ulinastatin molecules, and adsorbs little other impure proteins and interfering substances, so that the yield and purity of ulinastatin are effectively improved; moreover, the use of strong acid and strong base is avoided, the denaturation and inactivation of ulinastatin in the treatment process can be reduced to the greatest extent by adopting the technical means of combining vacuum concentration and freeze drying, and the biological activity of the final product is effectively guaranteed.

The application belongs to the technical field of biotechnology, and particularly relates to a method for extracting crude urokinase based on macroporous resin. The method significantly improves the specific activity and shelf life of the crude urokinase through a dynamic pH segmentation protection technology. In the process of lectin affinity chromatography, the high flow rate condition of the first stage pH 8.5-9.5 ensures the efficient and specific binding of urokinase and lectin, and the rapid removal of impure proteins; the dynamic adjustment of the second stage pH from 8.5-9.5 linearly to 7.5-8.5 in combination with low flow rate operation provides a mild microenvironment for urokinase molecules, effectively protecting the integrity of the sugar chain structure of the molecules. The added polyol and disaccharide complex protective agent can stabilize the protein conformation, prevent sugar chain degradation and modification, and reduce the impact of pH mutation on the protein structure. The addition of the complex protective agent further enhances the stability of the sugar chain structure, preventing enzymatic and chemical degradation during the chromatography process.

The present invention relates to a composition for treating thyroid eye disease comprising ulinastatin. Specifically, the composition of the present invention reduces the degree of ocular protrusion by inhibiting PAPP-A associated with thyroid eye disease, and reduces the expression of PAPP-A increased in intraocular tissue, thereby being effective in treating thyroid eye disease.

The invention relates to application of ulinastatin and tetrandrine in preparation of a medicine for preventing and / or treating radiation-induced lung injury, and belongs to the technical field of biological medicine. The invention provides application of ulinastatin combined with tetrandrine in preparation of a medicine for preventing and / or treating radiation-induced lung injury. The ulinastatin and the tetrandrine are combined to be used as a medicine for treating mice suffering from radiation-induced lung injury, and the result shows that the ulinastatin and the tetrandrine have very good treatment and prevention effects on the radiation-induced lung injury, and the ulinastatin and the tetrandrine are non-toxic to lung cells; growth and development of normal lung cells cannot be inhibited, the treatment effect does not have dose dependence, the content of pro-inflammatory cytokines TNF-alpha and IL-6 can be remarkably reduced, the symptom of lung tissue inflammation can be relieved, and the survival rate of mice suffering from radiation-induced lung injury can be increased.

The invention belongs to the technical field of biology, and particularly relates to a method for extracting an ulinastatin crude product based on macroporous resin. According to the method, the specific activity and shelf life of the ulinastatin crude product are remarkably improved and prolonged through a dynamic pH segmented protection technology. In the agglutinin affinity chromatography process, high-efficiency specific binding of ulinastatin and agglutinin is ensured under the high flow rate condition of pH 8.5-9.5 in the first stage, and impure protein is rapidly removed; in the second stage, dynamic adjustment of linearly reducing the pH value from 8.5-9.5 to 7.5-8.5 is matched with low-flow-speed operation, so that a mild microenvironment is provided for ulinastatin molecules, and the completeness of a sugar chain structure of the ulinastatin molecules is effectively protected. The added polyhydric alcohol and disaccharide composite protective agent can stabilize protein conformation, prevent sugar chain degradation and modification, and reduce the impact of pH mutation on the protein structure. The addition of the composite protective agent further enhances the stability of the carbohydrate chain structure, and prevents enzymolysis and chemical degradation in the chromatography process.

The invention is suitable for the technical field of wastewater treatment, and provides wastewater treatment equipment for ulinastatin production, the wastewater treatment equipment comprises an upper support plate, a middle support plate and a lower support plate which are sequentially mounted from top to bottom, the adjacent support plates are connected and fixed through a plurality of support columns, and the support columns for supporting are also fixedly mounted at four corners of the bottom of the lower support plate; the pretreatment tank is mounted at the top of the upper supporting plate; the adsorption tank is mounted at the top of the middle supporting plate; the recovery unit is mounted on the lower supporting plate; wherein a wastewater inlet pipe for conveying to-be-treated wastewater into the pretreatment tank is mounted at the top of the pretreatment tank, and a pretreatment unit is arranged in the pretreatment tank. The wastewater treatment equipment for ulinastatin production, provided by the scheme, is high in integration degree, adopts physical demulsification and catalytic oxidation cooperative treatment, is free of chemical pollution, synchronously realizes wastewater purification and salt recovery, and is adaptive to green production requirements.

The invention relates to the technical field of biological pharmacy, in particular to a method for extracting unimodal ulinastatin from human urine. The method sequentially comprises the following steps: carrying out primary capture and elution on human urine through ZGA313 resin chromatography; carrying out ultrafiltration desalination on the eluent by taking purified water as a buffer solution; adjusting the pH value of the desalted liquid, loading the desalted liquid to a monoclonal antibody chromatographic column of which the ligand is an antibody in a partial region of an ulinastatin Kunitz structural domain II, and carrying out specific affinity purification; the collected liquid is subjected to pasteurization virus inactivation and then is loaded to an RPC30 chromatographic column, and polymers generated in virus inactivation are selectively removed according to the difference of the number of polymer and monomer drainage points; and finally, replacing the buffer solution through ultrafiltration to obtain a single-peak ulinastatin solution. The method has the advantages of synergistic process step design, high specificity and pertinence, obvious improvement of the product purity and yield, effective removal of key impurities including polymers, guarantee of the product safety, simple and convenient operation, short period, and suitableness for large-scale production.

The invention discloses a stability-enhanced preparation method of ulinastatin freeze-dried powder injection, which belongs to the technical field of freeze-dried powder injection preparation, and comprises the following steps: ulinastatin is dissolved in water for injection, an excipient system is added to form a prescription solution to be freeze-dried, the excipient system at least comprises a crystal form skeleton excipient and a glassy state protection excipient, and the freeze-dried prescription solution is freeze-dried. Adding a buffer system to regulate and control the pH value of the prescription solution to be freeze-dried in a target window, and regulating and controlling the ion strength to enable the absolute value of the pH value drift under the freezing enrichment condition to be not greater than 0.5 pH unit; the prescription solution to be freeze-dried is sterilized, filtered and aseptically filled into a penicillin bottle, and the penicillin bottle enters a freeze-drying cavity after being half plugged; by introducing synchronous nucleation control of pressure triggering or external ice crystal triggering in the freezing stage, the nucleation time of each penicillin bottle tends to be consistent with the ice crystal structure, so that the problems of pore structure difference and large intra-batch fluctuation caused by inter-bottle nucleation randomness in the existing freeze-drying process are solved.